AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial
Condition.
On March16, 2017, AveXis,Inc. (the Registrant)
issued a press release announcing the Registrants financial
results for the fourth quarter and fiscal year ended December31,
2016, as well as information regarding a conference call to
discuss these financial results and the Registrants recent
corporate highlights and outlook, including certain information
related to the Registrants clinical data results for AVXS-101. A
copy of this press release is furnished herewith as Exhibit99.1
to this Current Report on Form8-K and is incorporated herein by
reference.
The information in this Item 2.02 of this Current Report on
Form8-K (including Exhibit99.1) is being furnished and shall not
be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or
otherwise subject to the liabilities of that Section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended (the Securities Act),
or the Exchange Act, except as expressly set forth by specific
reference in such a filing.
Item 7.01 Regulation FD
Disclosure.
As discussed in Item 2.02 above, the Registrant intends to
present certain information related to its clinical data results
for AVXS-101 during the March 16, 2017 conference call. A copy of
the slides to be presented during the call are furnished herewith
as Exhibit 99.2 to this Current Report on Form 8-K and are
incorporated herein by reference.
The information in this Item 7.01 of this Current Report on Form
8-K (including Exhibit 99.2) is being furnished and shall not be
deemed filed for purposes of Section 18 of the Exchange Act, or
otherwise subject to the liabilities of that Section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act or the Exchange Act, except as expressly set forth
by specific reference in such a filing.
Item 9.01. Financial Statements and
Exhibits.
(d)Exhibits
|
Exhibit |
|
|
|
Number |
|
ExhibitDescription |
|
99.1 |
Press Release, dated March16, 2017, titled AveXis Reports |
|
|
99.2 |
Slide Presentation dated March 16, 2017, titled AVXS-101 |
About AVEXIS, INC. (NASDAQ:AVXS)
AveXis, Inc., formerly Biolife Cell Bank, Inc., is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either carry a mutation in their SMN1 gene or their SMN1 genes have been deleted. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels. It also focuses to develop AVXS-101 to treat additional SMA types and other treatments for rare neurological genetic diseases. AVEXIS, INC. (NASDAQ:AVXS) Recent Trading Information
AVEXIS, INC. (NASDAQ:AVXS) closed its last trading session down -2.10 at 72.78 with 593,608 shares trading hands.